Dermagnostix offers needed comprehensive diagnostic solutions for dermatology. Point-of-care lab-on-a-chip devices are economic, fast, easy and precise.
In Europe alone, more than 100 million citizens suffer from chronic inflammatory skin diseases such as psoriasis or eczema. The diseases imply a devastating quality of life and cause direct socio-economic costs in the magnitude of 100 billion Euro each year in the EU, with clearly increasing tendency.
The last decades have brought a breakthrough for the therapy of inflammatory skin diseases. However, this therapeutic success was not paralleled by modern diagnostics, leaving a substantial proportion of patients misdiagnosed and consequently mistreated. Achieving true precision medicine requires feasible molecular diagnostics.
Dermagnostix is the first company to offer point-of-care molecular diagnostic devices for inflammatory skin diseases. Cost-efficient, fast, easy and precise. Our molecular test discriminates psoriasis from eczema based on the expression of only two markers in the skin - superior to any existing diagnostic method. It is performed as an easy-to-handle and economic microfluidic testing device - the LabDisk. Sample-in, answer-out in less than 1 hour.
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients’ lives and clinical practice in dermatology. Our multidisciplinary team unites expertise in dermatology, basic research, microfluidics and artificial intelligence to bring the most innovative products to market.
Proof-of-Concept Grant of the European Reserach Counsil 2018
Winner Science4Life Venture Cup - Phase 1
Winner Science4Life Venture Cup - Phase 2
7. place of the CyberOne Hightech Award Baden-Württemberg 2019
Finalist of the Münchener Businessplan Wettbewerb von BayStartUP 2019